How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Potent and Highly Selective Allosteric Inhibitors of PKC-zeta for the Treatment of Inflammatory Diseases and Cancer

Organization name

PVA Saarland

Profile

Background

Protein kinase C zeta (PKCζ) is implicated in the development of several inflammatory diseases and a promising therapeutic target. PKCζ controls TH2 response and is important for the regulation of NF-κB transcriptional activity. Moreover, there is increasing evidence for an involvement of PKCζ in tumor development, where it controls chemoresistance and cancer–related inflammation.

Invention

Scientists of Saarland University and German University in Cairo have discovered 1,3,5-trisubstituted and 1,3,4,5-tetrasubstituted pyrazolines as a potent and selective class of allosteric PKCζ inhibitors. Several of the compounds show inhibitory activity in the nanomolar range. The compounds have an allosteric mode of action by binding the less conserved PIF pocked domain and are highly selective for the specific PKC isoform.

Applications

The present technology opens up an innovative therapeutic approach for the treatment of inflammatory diseases in which the identified compounds can serve as starting points for drug development. First experiments indicate relevance particularly for chronic obstructive pulmonary disease (COPD).

Advantages

  • Innovative potent small molecules for selective PKCζ inhibition
  • Allosteric mode of action increases selectivity
  • Highly versatile scaffold for the independent optimization of four substituents
  • Specific targeting may contribute to fewer side effects
  • Potential treatment of diseases with high unmet medical need

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries